Abstract: Abstract：Objective To investigate the efficacy of febuxostat in hyperuricemic patients with chronic kidney disease and its influence in renal function. Methods All randomized controlled trials (RCTs) that focus on the efficacy of febuxostat and its effect on renal function in hyperuricemic patients with chronic kidney disease were screened from CNKI, CBM, WanFang, VIP, Embase, Pubmed, OVID and Cochrane library clinical controlled trials database. Data were extracted by two independent researchers, and the control of quality was evaluated from the modified Jadad rating scale. Meta analysis was then undertaken through RevMan 5.3 software. Results A total of 12 RCTs were obtained, including 1 031 patients with chronic kidney disease and hyperuricemia. Patients were divided into febuxostat group (n=516) and control group (n= 515). Meta-analysis results showed that the effects of febuxostat were significantly better than those of control group including serum uric acid (MD=-61.28, 95%CI: -67.68- -54.88, P ＜ 0.001), serum creatinine (MD=-31.51, 95%CI: -36.25- -26.76, P＜0.001), blood urea nitrogen (MD=-2.14, 95%CI: -2.87- -1.41, P＜0.001) and eGFR after treatment (MD=4.13, 95%CI: 1.67-6.58, P=0.001). There was no significant difference in the incidence of adverse reactions between the febuxostat group and the control group (OR=0.55, 95%CI: 0.15-1.92, P=0.35). Conclusion The current clinical evidences show that febuxostat has a better effect on the treatment of hyperuricemic patients with chronic kidney disease.

Key words: hyperuricemia, renal insufficiency, Meta-analysis, Febuxostat, chronic kidney disease